Monte Rosa Therapeutics annual return on equity
2021
2022
2023
2024
2025
Monte Rosa Therapeutics Return on Equity (ROE) Growth & History (GLUE)
Monte Rosa Therapeutics's return on equity was −16.94% for fiscal 2025.
View full Monte Rosa Therapeutics company overviewMonte Rosa Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −16.94% | +19.21 pp |
| 2024 | 2024-12-31 | −36.15% | +23.92 pp |
| 2023 | 2023-12-31 | −60.07% | −25.01 pp |
| 2022 | 2022-12-31 | −35.06% | +14.44 pp |
| 2021 | 2021-12-31 | −49.51% | — |
Monte Rosa Therapeutics quarterly return on equity
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −8.60% | −4.07 pp |
| Q1 2026 | 2026-03-31 | −11.79% | −30.61 pp |
| Q4 2025 | 2025-12-31 | −19.27% | −25.54 pp |
| Q3 2025 | 2025-09-30 | −10.54% | +0.55 pp |
| Q2 2025 | 2025-06-30 | −4.53% | +11.54 pp |
| Q1 2025 | 2025-03-31 | 18.83% | +38.10 pp |
| Q4 2024 | 2024-12-31 | 6.27% | +24.55 pp |
| Q3 2024 | 2024-09-30 | −11.09% | +6.43 pp |
| Q2 2024 | 2024-06-30 | −16.07% | −0.69 pp |
| Q1 2024 | 2024-03-31 | −19.27% | −6.83 pp |
| Q4 2023 | 2023-12-31 | −18.28% | −7.34 pp |
| Q3 2023 | 2023-09-30 | −17.52% | −8.31 pp |
| Q2 2023 | 2023-06-30 | −15.38% | −6.95 pp |
| Q1 2023 | 2023-03-31 | −12.44% | −5.33 pp |
| Q4 2022 | 2022-12-31 | −10.94% | −4.40 pp |
| Q3 2022 | 2022-09-30 | −9.21% | −3.75 pp |
| Q2 2022 | 2022-06-30 | −8.43% | +3.52 pp |
| Q1 2022 | 2022-03-31 | −7.11% | — |
| Q4 2021 | 2021-12-31 | −6.54% | — |
| Q3 2021 | 2021-09-30 | −5.46% | — |
| Q2 2021 | 2021-06-30 | −11.95% | — |
Monte Rosa Therapeutics return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Monte Rosa Therapeutics's return on equity increased from −49.51% to −16.94%, a change of +32.56 percentage points. The latest reported quarter, Q2 2026, shows −8.60%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Monte Rosa Therapeutics source filings ↗